Endocrine Pharmacology Practice Questions

Q: Which of the following antifungal agents is used in the treatment of Cushing's syndrome?

Ketoconazole. **Explanation:** **Ketoconazole** is the correct answer because it possesses a unique pharmacological profile that extends beyond its antifungal activity. At high doses, it acts as a potent inhibitor of several cytochrome P450 enzymes involved in steroid biosynthesis, most notably **11β-hydroxylase** and **17α-hydroxylase**. By blocking these enzymes, it effectively reduces the production of cortisol in the adrenal cortex, making it a first-line medical treatment for managing hypercortisolism in **Cushing’s syndrome** (especially when surgery is not an option or has failed). **Analysis of Incorrect Options:** * **Fluconazole:** While it is a widely used triazole for systemic candidiasis and cryptococcal meningitis, it is much more selective for fungal CYP450 enzymes and does not significantly inhibit human steroidogenesis. * **Itraconazole:** This is the drug of choice for histoplasmosis and blastomycosis. Like fluconazole, it lacks the potent inhibitory effect on adrenal steroid enzymes required to treat Cushing's. * **Miconazole:** This is primarily used as a topical agent for superficial fungal infections (like tinea or candidiasis) and does not have a systemic role in treating endocrine disorders. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action (Antifungal):** Inhibits 14α-demethylase, preventing the conversion of lanosterol to ergosterol. * **Adverse Effects:** Due to its non-selective inhibition of mammalian steroid enzymes, it can cause **gynecomastia**, decreased libido, and impotence in men (by inhibiting testosterone synthesis). * **Hepatotoxicity:** It carries a "Black Box Warning" for potentially fatal liver injury. * **Absorption:** It requires an **acidic gastric pH** for absorption; therefore, its efficacy is reduced if taken with antacids, H2 blockers, or PPIs.

Q: All of the following agents may be used in the management of Chronic Hypocalcemia, except:

Etidronate. **Explanation:** The goal of managing **Chronic Hypocalcemia** is to increase serum calcium levels and prevent long-term complications like osteomalacia or tetany. **Why Etidronate is the Correct Answer:** **Etidronate** is a first-generation **Bisphosphonate**. Bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption. By preventing the release of calcium from the bone into the bloodstream, they **lower serum calcium levels**. Therefore, Etidronate is used to treat *hypercalcemia* (e.g., malignancy-associated) and Paget’s disease, making it contraindicated and inappropriate for the management of hypocalcemia. **Analysis of Incorrect Options:** * **Elemental Calcium (Option C):** This is the mainstay of treatment. Oral calcium carbonate or calcium citrate is used to directly supplement and maintain serum calcium levels. * **Vitamin D Analogs (Option D):** Agents like Calcitriol or Alfacalcidol are essential as they increase the intestinal absorption of calcium and phosphate. * **Thiazides (Option B):** Unlike loop diuretics (which are "calciuric"), Thiazide diuretics **increase renal calcium reabsorption** in the distal convoluted tubule. They are often used as an adjunct in hypocalcemia to reduce hypercalciuria and prevent the formation of calcium stones. **NEET-PG High-Yield Pearls:** * **Acute Hypocalcemia:** Treated with IV Calcium Gluconate (preferred over Calcium Chloride due to less tissue irritation). * **Bisphosphonates:** Can cause "Hungry Bone Syndrome" or transient hypocalcemia after the first dose. * **Teriparatide (PTH analog):** Though it increases calcium, it is primarily used for osteoporosis, not as a first-line agent for chronic hypocalcemia unless it is due to hypoparathyroidism.

Q: What are the contents of Lugol's Iodine?

5% iodine and 10% potassium iodide. **Explanation:** Lugol’s Iodine (Strong Iodine Solution) is a classic pharmacological agent used in endocrine surgery. The correct composition is **5% elemental iodine and 10% potassium iodide (KI)** in distilled water. The potassium iodide acts as a solubilizing agent, allowing the elemental iodine to dissolve in water by forming polyiodide ions ($I_3^-$). **Why Option A is Correct:** The standard pharmaceutical preparation of Lugol's solution is defined by its 1:2 ratio of iodine to potassium iodide, specifically 5g of Iodine and 10g of Potassium Iodide per 100ml of solution. **Why Other Options are Incorrect:** Options B, C, and D provide incorrect concentrations and ratios. Deviating from the 5%/10% standard would either result in a solution that is too dilute to be clinically effective or too concentrated, increasing the risk of iodine toxicity and local irritation of the gastrointestinal mucosa. **Clinical Pearls for NEET-PG:** * **Mechanism of Action:** It works via the **Wolff-Chaikoff effect**, where high levels of plasma iodide acutely inhibit the organification of iodine, thereby decreasing the synthesis and release of thyroid hormones ($T_3$ and $T_4$). * **Surgical Utility:** In Graves' disease, it is administered 7–10 days preoperatively to **decrease the vascularity** and increase the firmness of the thyroid gland, making the surgery technically easier and safer. * **Limitation:** It should not be used long-term because of the "escape phenomenon," where the thyroid resumes hormone production after 10–14 days. * **Contraindication:** It should be avoided in patients with toxic multinodular goiter to prevent the **Jod-Basedow effect** (iodine-induced hyperthyroidism).

Q: The lymphocytopenia seen a few hours after administration of a large dose of prednisone to a patient with lymphocytic leukemia is due to?

massive lymphocytic apoptosis. **Explanation** The correct answer is **A. massive lymphocytic apoptosis.** **Mechanism of Action:** Glucocorticoids like prednisone exert potent lymphotoxic effects. When administered in pharmacological doses, they bind to intracellular glucocorticoid receptors, leading to the modulation of gene transcription. In lymphoid cells (specifically T-cells and neoplastic B-cells), this triggers a cascade of endonucleases that cause DNA fragmentation, resulting in **programmed cell death (apoptosis)**. This effect is rapid, occurring within a few hours, and is the primary reason steroids are used in the induction protocols for acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL). **Why other options are incorrect:** * **B. Bone marrow depression:** While steroids can suppress certain cell lines over long-term use, the acute drop in peripheral lymphocytes seen within hours is due to the destruction and redistribution of existing cells, not a failure of production in the marrow. * **C & D. Activation of cytotoxic/NK cells:** Glucocorticoids are actually **immunosuppressive**. They inhibit the function of cytotoxic T-lymphocytes and natural killer (NK) cells by suppressing cytokine production (like IL-2). They do not activate these cells to kill leukemic cells. **High-Yield NEET-PG Pearls:** * **Redistribution vs. Destruction:** Steroids cause lymphocytopenia, monocytopenia, and eosinopenia (due to redistribution to lymphoid tissue and apoptosis). Conversely, they cause **neutrophilia** (by decreasing the margination of neutrophils). * **Steroid-induced Psychosis:** A common side effect of high-dose prednisone that frequently appears in exams. * **Drug of Choice:** Dexamethasone is often preferred over prednisone for CNS involvement in leukemia due to its superior CNS penetration.

Q: Which of the following drugs acts by stimulating osteoblasts?

Teriparatide. ### Explanation The correct answer is **Teriparatide**. **1. Why Teriparatide is correct:** Teriparatide is a recombinant form of human **Parathyroid Hormone (PTH 1-34)**. While continuous high levels of PTH (as seen in hyperparathyroidism) cause bone resorption, **intermittent (pulsatile) administration** of Teriparatide has a paradoxical **anabolic effect**. It directly stimulates **osteoblasts** to form new bone, increases bone mineral density, and improves bone architecture. It is currently the only class of drugs (along with Abaloparatide) that primarily builds bone rather than just preventing its breakdown. **2. Why the other options are incorrect:** * **Raloxifene:** A Selective Estrogen Receptor Modulator (SERM). It acts as an estrogen agonist in bone, inhibiting **osteoclast** activity. It does not stimulate osteoblasts. * **Risedronate:** A Bisphosphonate. These drugs bind to hydroxyapatite crystals and are taken up by **osteoclasts**, inducing their apoptosis and inhibiting bone resorption. * **Denosumab:** A monoclonal antibody against **RANKL** (Receptor Activator of Nuclear Factor kappa-B Ligand). By inhibiting RANKL, it prevents the maturation and activation of **osteoclasts**. **3. NEET-PG High-Yield Pearls:** * **Mechanism:** Teriparatide increases the number and function of osteoblasts by activating the PTH1 receptor (a G-protein coupled receptor). * **Clinical Use:** Severe osteoporosis or patients who fail bisphosphonate therapy. * **Black Box Warning:** Risk of **Osteosarcoma** (observed in rat studies); hence, treatment is generally limited to a maximum of 2 years. * **Contraindications:** Paget’s disease of bone, prior radiation to the skeleton, or unexplained elevation of alkaline phosphatase.

Q: Which of the following statements regarding bromocriptine is true?

It acts as an agonist to dopamine receptors.. **Bromocriptine** is a semi-synthetic ergot alkaloid that acts as a potent **D2 receptor agonist** and a partial D1 antagonist [3, 2]. 1. **Why Option A is Correct:** Bromocriptine directly stimulates dopamine receptors in the tuberoinfundibular pathway (inhibiting prolactin release from the anterior pituitary) and the nigrostriatal pathway (improving motor control) [2]. This makes it a primary treatment for hyperprolactinemia, prolactinomas, and Parkinson’s disease [1, 2]. 2. **Why Other Options are Incorrect:** * **Option B:** Bromocriptine is **contraindicated** in patients with active peptic ulceration because it can increase the risk of gastrointestinal bleeding. * **Option C:** Postural (orthostatic) hypotension is a **common side effect** of bromocriptine, especially during the initiation of therapy (the "first-dose phenomenon"). Patients are often advised to take the first dose at bedtime. * **Option D:** Unlike newer non-ergot agonists like **Pramipexole** or **Ropinirole**, bromocriptine does not have proven neuroprotective effects. **High-Yield NEET-PG Pearls:** * **Drug of Choice (DOC):** While bromocriptine was traditionally used, **Cabergoline** is now the DOC for prolactinomas due to its higher efficacy, longer half-life (twice-weekly dosing), and better side-effect profile [1]. * **Specific Use:** Bromocriptine is specifically preferred over cabergoline when **pregnancy** is desired, as it has a longer track record of safety data in pregnancy. * **Other Indications:** It is also FDA-approved for the treatment of **Type 2 Diabetes Mellitus** (Quickrelease formulation) and Acromegaly [1]. * **Key Side Effects:** Nausea/vomiting (due to CTZ stimulation), digital vasospasm, and erythromelalgia [2].

Q: Which of the following drugs can cause osteonecrosis when administered intravenously?

Zolendronate. **Explanation:** **Zoledronate** (a potent intravenous bisphosphonate) is the correct answer. The underlying medical concept is **Medication-Related Osteonecrosis of the Jaw (MRONJ)**. Bisphosphonates inhibit osteoclast activity to prevent bone resorption. However, high-potency nitrogen-containing bisphosphonates like Zoledronate, especially when administered intravenously for bone metastases or Paget’s disease, can lead to impaired bone remodeling and decreased angiogenesis. This results in necrotic bone exposure in the maxillofacial region, typically following local trauma or dental surgery. **Analysis of Incorrect Options:** * **Dalteparin:** A Low Molecular Weight Heparin (LMWH) used as an anticoagulant. While long-term heparin use is associated with **osteoporosis**, it does not cause osteonecrosis. * **Calcitriol:** The active form of Vitamin D. It promotes calcium absorption and is used to treat hypocalcemia and metabolic bone disease; it is not associated with bone necrosis. * **Zidovudine:** A Nucleoside Reverse Transcriptase Inhibitor (NRTI) used in HIV. Its primary dose-limiting toxicity is **bone marrow suppression** (anemia/neutropenia) and myopathy, not osteonecrosis. **Clinical Pearls for NEET-PG:** * **MRONJ Risk Factors:** IV route (highest risk), long duration of therapy, and invasive dental procedures. * **Other Drugs:** Denosumab (RANKL inhibitor) and Anti-angiogenic agents (e.g., Bevacizumab) can also cause MRONJ. * **Management:** Patients should undergo a thorough dental examination and complete any necessary extractions *before* starting IV bisphosphonates. * **Zoledronate vs. Alendronate:** Zoledronate is given once yearly (IV) for osteoporosis, whereas Alendronate is given weekly (oral).

Q: Which bisphosphonate is approved for the treatment of osteoporosis and is administered on a yearly basis?

Zoledronate. **Explanation:** **Zoledronate (Zoledronic acid)** is the correct answer because it is the most potent bisphosphonate available. Due to its high affinity for mineralized bone and slow release from the bone matrix, it has a very long duration of action. For the treatment of postmenopausal osteoporosis, it is administered as a **5 mg intravenous infusion once yearly**. **Analysis of Incorrect Options:** * **Alendronate:** A first-line oral bisphosphonate typically administered **once weekly** (70 mg) or daily (10 mg). It must be taken on an empty stomach with a full glass of water to avoid esophageal irritation. * **Risedronate:** Another oral bisphosphonate administered either **daily, weekly, or monthly**. * **Ibandronate:** This can be administered **monthly (oral)** or **every three months (intravenous)**. It is not approved for yearly administration. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Bisphosphonates are pyrophosphate analogs that inhibit **osteoclast-mediated bone resorption** by inducing osteoclast apoptosis and inhibiting the mevalonate pathway (specifically the enzyme farnesyl pyrophosphate synthase). * **Adverse Effects:** * **Oral:** Erosive esophagitis (patients must remain upright for 30 minutes). * **IV (Zoledronate):** Acute phase reaction (flu-like symptoms) and potential nephrotoxicity. * **Class-wide:** Osteonecrosis of the jaw (ONJ) and atypical subtrochanteric fractures. * **Contraindication:** Avoid in patients with severe renal impairment (Creatinine Clearance <35 mL/min).

Q: Which of the following agents is not used in the treatment of erectile dysfunction?

Phenylephrine. **Explanation:** The correct answer is **Phenylephrine** because it is a potent **$\alpha_1$-selective adrenergic agonist**. [4] In the context of erectile physiology, sympathetic stimulation (via $\alpha_1$ receptors) causes vasoconstriction of the penile arteries and contraction of the trabecular smooth muscle, leading to detumescence (loss of erection). [1] Therefore, Phenylephrine is actually used to **treat priapism** (a prolonged, painful erection), not erectile dysfunction (ED). **Analysis of Incorrect Options:** * **Apomorphine (Option A):** A dopamine (D2) receptor agonist that acts centrally on the hypothalamus to initiate the erectile response. [3] It is used as a sublingual treatment for ED. * **Vardenafil (Option B):** A potent **PDE-5 inhibitor** (similar to Sildenafil). [2] It prevents the breakdown of cGMP in the corpus cavernosum, maintaining smooth muscle relaxation and enhancing blood flow. * **Alprostadil (Option D):** A synthetic **Prostaglandin E1 (PGE1)** analogue. It increases cAMP levels, leading to smooth muscle relaxation. It is administered via intracavernosal injection or intraurethral pellets. **Clinical Pearls for NEET-PG:** * **First-line treatment for ED:** Oral PDE-5 inhibitors (Sildenafil, Tadalafil, Vardenafil). * **Priapism Management:** Phenylephrine is the drug of choice (administered via intracavernosal injection). * **Contraindication:** PDE-5 inhibitors must never be used with **Nitrates**, as they can cause synergistic peripheral vasodilation leading to severe, life-threatening hypotension. [2] * **Alprostadil** is also used to maintain the patency of the **Ductus Arteriosus** in neonates with cyanotic heart disease.

Question 1

Which of the following antifungal agents is used in the treatment of Cushing's syndrome?

Accepted Answer

Ketoconazole

Answer

Fluconazole

Answer

Itraconazole

Answer

Miconazole

Question 2

All of the following agents may be used in the management of Chronic Hypocalcemia, except:

Accepted Answer

Etidronate

Answer

Thiazides

Answer

Elemental calcium

Answer

Vitamin D analogs

Question 3

What are the contents of Lugol's Iodine?

Accepted Answer

5% iodine and 10% potassium iodide

Answer

10% iodine and 20% potassium iodide

Answer

10% iodine and 15% potassium iodide

Answer

5% iodine and 15% potassium iodide

Question 4

The lymphocytopenia seen a few hours after administration of a large dose of prednisone to a patient with lymphocytic leukemia is due to?

Accepted Answer

massive lymphocytic apoptosis

Answer

bone marrow depression

Answer

activation of cytotoxic cells

Answer

stimulation of natural killer cell activity

Question 5

Which of the following drugs acts by stimulating osteoblasts?

Accepted Answer

Teriparatide

Answer

Raloxifene

Answer

Risedronate

Answer

Denosumab

Question 6

Which of the following statements regarding bromocriptine is true?

Accepted Answer

It acts as an agonist to dopamine receptors.

Answer

It can be used in active peptic ulceration.

Answer

It does not cause postural hypotension.

Answer

It has possible neuroprotective effects.

Question 7

A 35-year-old woman with active lupus nephritis experiences a fall onto her left hand, resulting in immediate pain and crepitus at the wrist on examination. Radiographs reveal radial and navicular fractures along with marked osteopenia. Which of the following medications most likely contributed to the fracture?

Accepted Answer

Hydrocortisone

Answer

Ibuprofen

Answer

Lisinopril

Answer

Losartan

Question 8

Which of the following drugs can cause osteonecrosis when administered intravenously?

Accepted Answer

Zolendronate

Answer

Dalteparin

Answer

Calcitriol

Answer

Zidovudine

Question 9

Which bisphosphonate is approved for the treatment of osteoporosis and is administered on a yearly basis?

Accepted Answer

Zoledronate

Answer

Alendronate

Answer

Risedronate

Answer

Ibandronate

Question 10

Which of the following agents is not used in the treatment of erectile dysfunction?

Accepted Answer

Phenylephrine

Answer

Apomorphine

Answer

Vardenafil

Answer

Alprostadil

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?